CPT1A is highly expressed in prostate cancer (124), nasopharyngeal carcinoma (125, 126), glioblastoma (127), etc. Inhibition of CPT1A significantly inhibits tumor growth, improves survival, and increases the sensitivity of nasopharyngeal carcinoma to radiotherapy (125). The gene discussed is CPT1A; the disease is neoplasm.